| Company* (Country; Symbol) | Company (Country; Symbol) | Type/Product Area | Terms/Details (Date) |
| I. MODIFIED AGREEMENTS | |||
| Abbott Laboratories (NYSE:ABT) | Caprion Proteomics* (Canada) | Extended partnership to investigate viable human therapeutic antibody targets for oncology using Caprion's CellCarta tech- nology platform | The agreement allows Abbott to retain exclusive rights to 10 targets in lung cancer identified by Caprion for up to two years (6/6) |
| CombinatoRx Inc. (CRXX) | Angiotech Pharmaceuticals Inc. (ANPI) | Extended collaboration based upon the successful advance- ment of a number of product candidates in relevant preclinical models | The research aims at creating next-generation drug devices and local medicines; the deal was extended to a total of five years, resulting in a $7M payment to CombinatoRx due before Oct. 3 (6/12) |
| Dyax Corp. (DYAX) | Trubion Pharmaceuticals Inc. (TRBN) | Expanded research agreement, which covers protein therapeutics and diagnostics discovery | Dyax will transfer its phage library to Trubion's facility for use in identifying therapeutic leads to additional targets (5/22) |
| Repligen Corp. (RGEN) | Applied Biosystems (NYSE:ABI) | Expanded relationship; entered a new four-year supply agreement for recombinant Protein A | Specific terms were not disclosed (6/6) |
| Notes: | |||
| * Private companies are indicated with an asterisk. | |||
| Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
| NYSE = New York Stock Exchange. | |||
